Organovo Holdings, Inc. (NASDAQ:ONVO – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 145,300 shares, a growth of 271.6% from the October 15th total of 39,100 shares. Based on an average daily volume of 65,300 shares, the short-interest ratio is currently 2.2 days.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Organovo in a report on Monday. They set a “sell” rating on the stock.
Check Out Our Latest Report on ONVO
Organovo Stock Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC acquired a new position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned 6.46% of Organovo as of its most recent SEC filing. 8.23% of the stock is owned by institutional investors.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Stories
- Five stocks we like better than Organovo
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Rocket Lab is the Right Stock for the Right Time
- What is a SEC Filing?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.